NON-GMP SYNTHESIS OF COMPOUNDS FOR DRUG DEVELOPMENT

用于药物开发的非 GMP 化合物合成

• 批准号: 10246234
• 负责人: VLADIMIR RUDCHENKO
• 金额: $ 62.76万
• 依托单位: ALCHEM LABORATORIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-20 至 2021-09-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10246234
• 关键词: Biological; Contracts; Evaluation; Investigational Therapies; Malignant Neoplasms; Methodology; Mission; Pharmaceutical Preparations; Recommendation; analog; chemical synthesis; drug development; programs

The mission will be “Non-GMP” chemical synthesis of compounds of good purity as needed for the cancer program, such as synthetic compounds mainly prompted by the NCI Experimental Therapeutics (NExT) and Drug Acquisition Initiative (DAI) programs and also compounds arising from the recommendation of the Biological Evaluation Committee (BEC). The contract may be utilized for the purpose of synthesis of active single compound leads and their analogs using parallel synthesis methodology, as sometimes required by programmatic needs.

这项任务将是癌症计划所需的高纯度化合物的“非GMP”化学合成， 如合成化合物主要由NCI实验治疗学(NEXT)和药物获取推动 倡议(DAI)计划以及生物评估建议产生的化合物 委员会(BEC)。该合同可用于合成活性单组分化合物引线及其 使用并行综合方法的类比，有时是程序需要的。